Acute Myocardial infarction is responsible for substantial mortality and morbidity all over the world. Biomarkers assists in timely diagnosis, prediction and ease clinicians in tailoring appropriate therapy for high-risk patients of acute myocardial infarction. AMI patients can be stratified by symptoms, risk factors and electrocardiogram results but cardiac biomarkers also have significance in diagnosis and prognosis. Presently, troponin is the gold standard biomarker for myocardial insult and is used concurrently with creatine kinase-MB (CK-MB) and myoglobin for a quick and precise diagnosis of acute coronary syndrome (ACS). Novel biomarkers discussed here are Myoglobin, Creatine kinase, Lactate dehydrogenase, Ischaemia modified albumin (IMA), Troponin, Copeptin, Growthdifferentiation factor-15(GDF-15), CD40L, Myeloperoxidase (MPO), ET1/CTproET1, ST2, Circulating microRNA’s, B-type Natriuretic peptide, Mid-regional pro-atrial natriuretic peptide. This review focuses on a variety of promising biomarkers which provide diagnostic and prognostic information of acute myocardial infarction. This may facilitate doctors for appropriate therapy to high-risk patients
